Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics was planning to go public, but the IPO was withdrawn on Jun 9, 2025.
Stock Price: Pending
IPO price not available yet
Odyssey Therapeutics Revenue
Odyssey Therapeutics had revenue of $3.00M in the twelve months ending September 30, 2024. In the year 2023, Odyssey Therapeutics had annual revenue of $1.04M.
Revenue (ttm)
$3.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$19,894
Employees
151
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.04M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionODTX News
- 7 days ago - Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development - Business Wire
- 5 weeks ago - Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire
- 2 months ago - Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs - GlobeNewsWire
- 2 months ago - Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases - Business Wire
- 9 months ago - U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
- 10 months ago - U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
- 10 months ago - Odyssey Therapeutics Begins IPO Rollout - Seeking Alpha
- 10 months ago - Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO - Renaissance Capital